ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Trimethylamine N-Oxide Combined with Phenylacetylglutamine as Potential Biomarkers for Diabetic Kidney Disease.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: For diabetic kidney disease (DKD), a serious complication of diabetes mellitus, this study was designed to assess the potential utility of two gut microbiota-derived metabolites - trimethylamine N-oxide (TMAO) and phenylacetylglutamine (PAGln) - individually and in combination for identifying DKD. Methods: Plasma TMAO and PAGln levels were quantified by Liquid chromatography-tandem mass spectrometry (LC-MS/MS) in 165 patients with type 2 diabetes mellitus (T2DM) (63 without nephropathy and 102 with DKD). Spearman correlation analysis was performed to evaluate the associations between metabolite concentrations and renal function metrics. Multivariable logistic regression and Receiver operating characteristic (ROC) analyses were performed to evaluate independent risk associations and the potential of the metabolites to indicate DKD. Results: DKD patients showed significantly higher plasma TMAO and PAGln levels than T2DM subjects without nephropathy. Both metabolites correlated positively with blood urea nitrogen, serum creatinine, uric acid, microalbuminuria and urine albumin-to-creatinine ratio and negatively with estimated glomerular filtration rate, and each emerged as an independent correlate of DKD. ROC analysis gave area under the curve (AUC) values of 0.795 for TMAO and 0.832 for PAGln; combining the two metabolites raised the AUC to 0.846, with a substantial increase in sensitivity from 65.7% (TMAO alone) and 68.3% (PAGln alone) to 75.6%, while maintaining high specificity (85.2%). Conclusion: TMAO and PAGln are independent biomarkers of DKD. Their combined use significantly improved sensitivity while maintaining high specificity, offering a powerful, non-invasive strategy for identification of DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.